Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.

How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.

Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests

Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.